Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE:MDT) completed its acquisition of CathWorks on April 20, 2026, valuing the deal at $585 million with potential undisclosed earn-outs. The purchase adds the CathWorks FFRangio® System—an AI-driven, drug-free, wire-free angiography-derived physiologic assessment—commercially available in the U.S., Europe and Japan.
The ALL-RISE randomized trial (1,900+ patients) showed FFRangio is non-inferior to wire-based FFR for one-year MACE, supporting clinical adoption; Medtronic says the deal is immaterial to FY2027 GAAP and adjusted EPS and neutral to accretive thereafter.
Medtronic (NYSE: MDT) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. The company ends its fiscal year on April 24, 2026.
A news release with summary financial information will be issued at 5:45 a.m. Central Time, followed by a video webcast at 6:45 a.m. CT. A replay and transcript will be posted within 24 hours at the investor relations events page. Contacts for media and investor relations are provided.
Medtronic (NYSE: MDT) received FDA clearance for the Stealth AXiS™ surgical system for cranial and ENT procedures on March 27, 2026. The system unifies planning, navigation, robotics and AI-enabled tractography inside the AiBLE™ ecosystem, and was cleared for spine in February.
The platform integrates intraoperative ultrasound via GE HealthCare bkActiv™ and is designed for continuous software innovation and multi-specialty connectivity.
Medtronic (NYSE: MDT) received FDA approval (March 23, 2026) for an expanded indication for the OmniaSecure defibrillation lead to enable placement in the left bundle branch (LBB) area for conduction system pacing (CSP).
The lumenless, 4.7 French lead is approved for adults and adolescent patients ages 12+, showed 100% defibrillation success at implant and a 2.1% OmniaSecure-related major complication rate at three months in the LEADR LBBAP trial, and commercially launched in the U.S. in January 2026.
Medtronic (NYSE:MDT) agreed to acquire Scientia Vascular for $550 million, subject to customary adjustments and potential earn‑outs, to integrate Scientia's guidewires and catheters into Medtronic's neurovascular portfolio.
The deal covers ~310 employees, targets faster access in stroke care, is expected to close in 1H FY27, and is forecast to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed Group (planned Nasdaq: MMED) priced an initial public offering of 28,000,000 shares at $20.00 per share, with expected Nasdaq trading to begin March 6, 2026 and closing of the offering expected March 9, 2026, subject to customary conditions.
MiniMed granted underwriters a 30-day option for up to 4,200,000 additional shares. Upon completion, Medtronic is expected to retain approximately 90.03% ownership (88.70% if the over-allotment is fully exercised). Proceeds will fund general corporate purposes and may repay intercompany debt to Medtronic.
Medtronic (NYSE: MDT) announced a cash dividend of $0.71 per ordinary share for the fourth quarter of fiscal 2026. The board approved the dividend on March 5, 2026, payable April 17, 2026, to shareholders of record at the close of business on March 27, 2026.
Medtronic noted this quarterly declaration aligns with its May 2025 dividend increase and highlighted its 48-year streak of consecutive annual dividend increases as a member of the S&P 500 Dividend Aristocrats.
Medtronic (NYSE:MDT) announced that Thierry Piéton, executive vice president and chief financial officer, will appear in fireside chats at two investor conferences on March 10–11, 2026.
Live webcasts will be available via the company's investor events page, with archived recordings posted later the same day.
Medtronic (NYSE: MDT) launched the MiniMed Go™ Smart MDI system with the Simplera™ sensor across Europe beginning Feb 2026. The system integrates InPen™ smart insulin pen and Simplera™ CGM into one app, offering real-time dose calculation, missed-dose alerts, CareLink Clinic MDI reports, and expanded pediatric labeling.
Rollout is gradual across Europe; Instinct Go™ compatibility is pending CE mark and Simplera™ compatibility in the U.S. is under FDA review.